Heparin Sodium And Dextrose Injection, Solution
NDC Package 0409-4520-30

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Heparin Sodium And Dextrose (heparin sodium) injection is heparin sodium is indicated for:    Atrial fibrillation with embolization;    Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation);    Prevention of clotting in arterial and heart surgery;    Prophylaxis and treatment of peripheral arterial embolism;    As an anticoagulant in extracorporeal arterial circulation and dialysis procedures. This formulation utilizes a injection, solution delivery system. Marketed by Hospira, Inc., this product is identified by NDC 0409-4520 and is authorized under FDA application NDA019339.

Identification & Billing

NDC Package Code
0409-4520-30
Package Description
30 POUCH in 1 CASE / 1 BAG in 1 POUCH / 250 mL in 1 BAG (0409-4520-02)
Product Code
0409-4520
11-Digit Billing Format
00409452030
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 1658717 - heparin sodium, porcine 25,000 UNT in 250 ML Injection
  • RxCUI: 1658717 - 250 ML heparin sodium, porcine 100 UNT/ML Injection
  • RxCUI: 1658717 - heparin sodium, porcine 25,000 UNT per 250 ML Injection

Clinical Specifications

Proprietary Name
Heparin Sodium And Dextrose
Non-Proprietary Name
Heparin Sodium
Substance Name
Heparin Sodium
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
HEPARIN SODIUM 10000 [USP'U]/100mL
Pharmacologic Class
Usage Information
Heparin sodium is indicated for:    Atrial fibrillation with embolization;    Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation);    Prevention of clotting in arterial and heart surgery;    Prophylaxis and treatment of peripheral arterial embolism;    As an anticoagulant in extracorporeal arterial circulation and dialysis procedures.

Regulatory & Marketing

Labeler Name
Hospira, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA019339
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-12-2022
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J1644
Source: PDAC
INJECTION, HEPARIN SODIUM, PER 1000 UNITS
HCPCS Dosage 1000 U
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0409-4520-30 identifies a specific commercial package of 30 pouch in 1 case / 1 bag in 1 pouch / 250 ml in 1 bag (0409-4520-02) of Heparin Sodium And Dextrose, a human prescription drug labeled by Hospira, Inc.. This injection, solution is formulated for intravenous use and contains heparin sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hospira, Inc. on December 12, 2022. The current certification is valid through December 31, 2027.

How is this Hospira, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00409452030. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0409-4520-30
11-Digit CMS (5-4-2)
00409-4520-30

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.